Clinical trials: Antiviral Agents
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
SHARP-P is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-P (NCT03740906)
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
COVID-19
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19…
- Trial name
- CRISIS (NCT04425252)
- Testing
- Brequinar, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Clear Creek Bio, Inc.
HIV Infections
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC.
- Trial name
- NCT00002001
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 5 sites in United States, Australia and 1 more
- Sponsor
- Glaxo Wellcome
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis
- Trial name
- NCT01995071
- Testing
- ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333
- Volunteers
- 89 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
- Trial name
- NCT00040144
- Testing
- ACH126, 433
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV-1 Infection, HIV Infection
Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage
Background: Neuropsychiatric side effects (NPSEs) occur in a significant proportion of subjects after initiation of efavirenz (EFV) and may limit its use in certain patients.
- Trial name
- NCT00556634
- Testing
- Efavirenz
- Where
- 10 sites in Spain
- Volunteers
- 114 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
HIV Infections
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
To generate initial information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess the safety and tolerance of single rising oral doses of…
- Trial name
- NCT00000634
- Testing
- Nevirapine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
Antiviral Activity of Oral Probiotics
The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.
- Trial name
- NCT05374070
- Testing
- Streptococcus salivarius K12 Powder 1 Billion colony forming units /g), Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included, Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- John Hale
HIV Infections
A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
To study the toxicity, pharmacokinetics, and antiretroviral effectiveness of combined oral zidovudine (AZT) and intermittent intravenous foscarnet therapy in stable AIDS or AIDS related complex (ARC) patients who have already…
- Trial name
- NCT00001002
- Testing
- Zidovudine, Foscarnet sodium
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy.
- Trial name
- NCT02960581
- Testing
- PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Hepatitis B, Hepatitis C
Dynamic Liver Tests in Liver Disease
Chronic viral hepatitis often leads to liver scarring - cirrhosis. If the virus is eradicated from the liver, the liver scarring and liver function often recovers.
- Trial name
- NCT02782247
- Testing
- Transient elastography, Indocyanine Green excretion
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Queen Mary University of London
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function…
- Trial name
- CICHepC (NCT02745132)
- Testing
- Neuropsychological evaluation and Brain MRI
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
HIV Infection
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there…
- Trial name
- NCT00001644
- Testing
- Indinavir, Zidovudine, Lamivudine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic…
- Trial name
- NCT02822794
- Testing
- SOF/VEL, RBV
- Where
- 18 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
Hepatitis B, Pregnancy
Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection
Most new hepatitis B virus (HBV) infections are acquired perinatally. In this study, pregnant women with HBsAg and HBeAg will receive tenofovir disoproxil fumarate during the last trimester of pregnancy and for two months…
- Trial name
- NCT03343431
- Testing
- Anti-HBV antiviral prophylaxis
- Where
- 20 sites in Laos, Thailand
- Volunteers
- 504 people
- Sponsor
- Institut de Recherche pour le Developpement
Anemia, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo for the treatment of anemia in AIDS (Acquired Immunodeficiency Syndrome) patients with anemia that is a result of this disease…
- Trial name
- NCT00269945
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.